Trials / Completed
CompletedNCT04555733
A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants
An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lemborexant in Healthy Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of lemborexant and metabolites (M4, M9, and M10) in plasma in healthy Chinese participants following single and multiple oral doses of lemborexant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lemborexant | Lemborexant oral tablets. |
Timeline
- Start date
- 2020-10-26
- Primary completion
- 2021-01-13
- Completion
- 2021-01-13
- First posted
- 2020-09-21
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04555733. Inclusion in this directory is not an endorsement.